Education
About Us
Working with TipRanks
Follow Us
Lineage Cell Therapeutics, Inc. (LCTX)
:LCTX
Total Valuation
Lineage Therap has a market cap or net worth of $107.28M. The enterprise value is $139.60M.
Market Cap$107.28M
Enterprise Value$139.60M
Share Statistics
Lineage Therap has 228.36M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding228.36M
Owned by Insiders53.70%
Owned by Instutions0.79%
Financial Efficiency
Lineage Therap’s return on equity (ROE) is -0.24 and return on invested capital (ROIC) is -21.18%.
Return on Equity (ROE)-24.16%
Return on Assets (ROA)-16.44%
Return on Invested Capital (ROIC)-21.18%
Return on Capital Employed (ROCE)-21.64%
Revenue Per Employee$135,700
Profits Per Employee-$265,842.857
Employee Count70
Asset Turnover0.08
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lineage Therap is -5.41. Lineage Therap’s PEG ratio is 0.24.
PE Ratio-5.41
PS Ratio10.59
PB Ratio1.31
Price to Fair Value1.31
Price to FCF-4.36
Price to Operating Cash Flow-4.36
PEG Ratio0.24
Income Statement
In the last 12 months, Lineage Therap had revenue of $9.50M and earned -$18.61M in profits. Earnings per share was -$0.11.
Revenue$9.50M
Gross Profit$8.99M
Operating Income-$21.48M
Pretax Income-$18.58M
Net Income-$18.61M
EBITDA-20.87M
Earnings Per Share (EPS)-0.11
Cash Flow
In the last 12 months, operating cash flow was -$23.09M and capital expenditures -$365.00K, giving a free cash flow of -$23.46M billion.
Operating Cash Flow-$23.09M
Free Cash Flow-$23.46M
Free Cash Flow per Share-$0.10
Dividends & Yields
Lineage Therap pays an annual dividend of $0.11, resulting in a dividend yield of
Dividend Per Share$0.11
Dividend Yield
Payout Ratio
Free Cash Flow Yield-22.95%
Earnings Yield-18.50%
Stock Price Statistics
Beta0.90
52-Week Price Change-61.74%
50-Day Moving Average0.55
200-Day Moving Average0.74
Relative Strength Index (RSI)43.62
Average Volume (3m)1.71M
Important Dates
Lineage Therap upcoming earnings date is May 8, 2025, Before Open.
Last Earnings DateMar 10, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend DateNov 29, 2018
Financial Position
Lineage Therap as a current ratio of 3.65, with Debt / Equity ratio of 0.03
Current Ratio3.65
Quick Ratio3.65
Debt to Market Cap0.02
Net Debt to EBITDA2.01
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lineage Therap has paid $17.00K in taxes.
Income Tax$17.00K
Effective Tax Rate-0.15%
Enterprise Valuation
Lineage Therap EV to EBITDA ratio is -2.67, with an EV/FCF ratio of -2.48.
EV to Sales6.03
EV to EBITDA-2.67
EV to Free Cash Flow-2.48
EV to Operating Cash Flow-2.48
Balance Sheet
Lineage Therap has $47.80M in cash and marketable securities with $2.51M in debt, giving a net cash position of -$45.29M billion.
Cash & Marketable Securities$47.80M
Total Debt$2.51M
Net Cash-$45.29M
Net Cash Per Share-$0.20
Tangible Book Value Per Share$0.10
Margins
Gross margin is 96.48%, with operating margin of -226.11%, and net profit margin of -195.90%.
Gross Margin96.48%
Operating Margin-226.11%
Pretax Margin-195.62%
Net Profit Margin-195.90%
EBITDA Margin-226.11%
EBIT Margin-226.11%
Analyst Forecast
The average price target for Lineage Therap is $4.13, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$4.13
Price Target Upside838.64%
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast6.19%
EPS Growth Forecast22.05%